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OBJECTIVES: Hunter syndrome (HS) is a rare X-linked progressive multi-systemic
lysosomal storage disease. The 55 item child and 68 item parent versions of the 8
domain HS-FOCUS questionnaire were used to monitor the safety and efficacy with
enzyme replacement therapy (ERT) in clinical trials. The objective was to validate
HS-FOCUS according to the FDA PRO Guidance. METHODS: HS-FOCUS data col-
lected in a placebo-controlled trial (53 weeks, plus 36 months extension) were used
to evaluate item performance, reliability, validity, and responsiveness. RESULTS:
Altogether, 55 children and 84 parents completed the HS-FOCUS at baseline and
follow up visits. High percentage of lowest item response ( 60%) and high average
inter-item correlations suggested that some items were less informative or redun-
dant. The internal consistency met the0.70 criteria for all domains in parents and
children, except the breathing domain in children. The test-retest reliability was
0.70 for Walking/Standing, School/Work, Activities, and Overall Function do-
mains in parents, and for Walking/Standing and Activities domains in children.
The construct validity correlating the HS-FOCUS with Childhood Health Assess-
ment Questionnaire (CHAQ) showed moderate to high correlations in related con-
cepts, especially in activity related domains. Correlations with lung function (FEV1)
ranged from -0.06 (School/Work) to -0.48 (Breathing). Significantly score differences
were found in most domains among tertiles based on overall-well being and pain
VAS. Responsiveness showed large effect sizes, especially for Sleep, Breathing and
School/work domains (0.50-1.07). CONCLUSIONS: Developing disease-specific
PROs for rare diseases is challenging due to the nature of the evidence base. This
study demonstrates HS-FOCUS to be a reliable, valid, and responsive instrument
which can be applied in clinical trials or disease registries. The questionnaire can
be streamlined by reducing item redundancy without compromising its validity.
Simultaneously, an item bank may be generated which could serve as a basis for
developing questionnaires for other mucopolysaccharidosis disorders.
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OBJECTIVES: The PedsQL™ Measurement Model is a modular approach to measur-
ing health-related quality of life (HRQOL) in healthy children and adolescents and
those with acute and chronic health conditions. Several Spanish versions for use in
different Spanish speaking countries were developed. The objectives of this study
were to compare these Spanish versions, quantify and qualify the differences and
conclude on the need (or not) for country-specific Spanish versions.METHODS:Our
study focused on the Teen form (13-18) and included the following steps: 1.Collec-
tion of the validated Spanish versions in collaboration with the author; 2.Identifi-
cation of the differences in items, and response scales; and 3. Coding of the differ-
ences as Cultural (C), Lexical (L), Idiomatic (I) and Syntactical (S). RESULTS: Six
validated Spanish versions were retrieved: Spanish for US, Spain, Argentina, Chile,
Mexico and Peru. Since it was the first translated, the US Spanish version served as
comparator. All versions showed differences. Spanish for Spain showed the high-
est number of differences (57), then Chile (47), Argentina (36), Peru (20) and Mexico
(18). None of the differences were cultural. In 65% of the cases, the divergences
were idiomatic. For instance, the expression “Se me hace difícil” (It is hard for me)
used in US Spanish was replaced in all corresponding items by “Me cuesta” (Liter-
ally “It costs me”) in Spain, Argentina and Chile. The time recall sentence and item
3 of the School Functioning Scale showed most of the differences. One of the
reasons could be the use of a very idiomatic form in the original US English version:
“I have trouble keeping up”. It should be noted that items of the Emotional Func-
tioning Scale showed very few differences. CONCLUSIONS: Numerous changes in
wording for idiomatic reasons indicating respondents preferences point to the
necessity of developing specific Spanish versions of the PedsQL™.
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OBJECTIVES: The individualised expectations of the patient will undoubtedly be
one of the major preoccupations in the next few decades to guarantee optimal
treatment through compliance. METHODS: A pragmatic, European cohort (France,
Italy, and Portugal) of 477 patients presenting with urinary disorders, evocative of
BPH, was followed-up over 6 months. A questionnaire regarding expectations was
handed out at the first consultation. RESULTS: A total of 441 patients were evalu-
ated. The symptom that 31,11% of patients wished to see improved with the high-
est priority were “getting up in the night to urinate”, then for 20%, “sensation of not
emptying the bladder after urinating . Amongst the symptoms that patients were
the least concerned about were the effort or force needed to start urinating for
26,80% of responders, then “size and force of the stream of urine for 15,38% and
the interruption of the flow of urine for 13,40%.“Getting up in the night” was the
principal complaint in all 3 countries (36,30% in France, 29 and 27,54% in Portugal
and Italy), whereas the effort or force needed to start urinating is the symptom
that preoccupies the patients the least in France and Italy, and the “size and force
of the stream of urine” preoccupies the Portuguese the least.Nearly 87% of the
Italians claimed that they would only be satisfied if they never had to get up in the
night again, (35% for the French, 67% for the Portuguese).Overall, 60% of the sub-
jects questioned said that they would be satisfied if they were “markedly”
improved. CONCLUSIONS: The expectation of patients in the treatment of BPH is
very important, and undoubtedly difficult to satisfy entirely. These results are
probably due to the fact that our population was composed of patients that had
been diagnosed recently.
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OBJECTIVES: The objective of the study was to assess the effect of changes in
health-related behaviours on academic achievement and on HRQOL of children
and adolescents aged 8 – 18 years in a 3 years follow-up study. METHODS: A rep-
resentative sample of Spanish children and adolescents aged 8-18 years participat-
ing in the KIDSCREEN follow-up study completed the self-administered HRQOL
questionnaire KIDSCREEN-27, and questions regarding smoking and drinking hab-
its (binge drinking), among others at baseline (2003) and 3 years after (2006). Aca-
demic achievement, a scale of the Child Health and Illness Profile (CHIP), was
collected at follow-up. Data on gender and family socio-economic status was also
collected. Multivariate linear regression analysis was performed to assess the in-
fluence of changes in health-related behaviours on academic achievement and
HRQOL controlling for socioeconomic and family factors. RESULTS: Response rate
at follow-up was 54% (n454). Twenty six percent of the sample reported ever use
of tobacco, while 4.6% reported to have started or to be a current regular smoker at
follow-up; 18% reported starting or increasing alcohol consumption, and 16.5% on
substance consumption (mainly cannabis). Preliminary multivariate analyses
show that becoming a current smoker during the follow-up period was associated
to worse Academic achievement among girls (beta coefficient-5.0; p 0.02); re-
porting ever drug consumption was associated with worse Psychological well-be-
ing among girls (beta -3.1; p0.04), and with worse Physical well-being among
boys (beta -5.9; p0.004), at the follow-up. CONCLUSIONS: Changes in health-
related behaviours are associated with worse outcome at 3 years of follow-up.
Future studies should analyse factors related to susceptibility for regular use of
tobacco and other drugs. Policy initiatives, and other factors should be taken into
account preventing tobacco and other substance use at these ages.
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OBJECTIVES: Studies often examine the impact of specific chronic conditions (CC)
in isolation or in conjunction with another specific CC. Our aims were to compare:
1) the effect of physical CCs (PCC) in addition to mental CCs (MCC) to the effect of
PCCs only; 2) the effect of MCCs in addition to PCCs to the effect of MCCs only; and
3) effects across country. METHODS: Data from the 2010 EU National Health and
Wellness Survey were used (N57,805; France, Germany, Italy, Spain, and the UK).
Respondents were categorized as: ‘Healthy’ (no mental or physical CC); ‘Physical’
(physician indicated 1 physical but no mental CCs); ‘Mental’ (physician indicated
1mental but no physical CCs); ‘Physical and Mental’ (1mental and 1 physical
CCs). Differences across groups were assessed using multivariate regression with
SF-12v2® Health Survey summary measures (PCS & MCS) as outcomes and control-
ling for age and gender. RESULTS: Relative to ‘Healthy’ respondents, the presence
of 1 PCC was associated with a significant decrement in both PCS (-3.04 to -5.18,
p.05) and MCS (-1.23 to -2.53, p.05). The presence of 1 mental condition was
also associated with decreased MCS (-7.10 to -13.30, p.05) and PCS (-1.23 to -2.53,
p.05). Interestingly, the impact of co-morbid conditions, physical or mental, var-
ied as a function of other existing conditions (physical or mental). The impact of
adding 1 PCC to an existing MCC was associated with a larger decrement in PCS
(-4.34 to -6.92, p.05) and MCS (-8.54 to -11.70, p.05) as compared to adding 1 PCC
to those who were healthy. Results were consistent across gender and country.
CONCLUSIONS: These findings (which are largely consistent an earlier US study)
highlight the complexity of managing patients with co- or multi-morbid CCs as the
measurable burden of CCs varies with the presence of other conditions.
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OBJECTIVES:Herpes zoster (HZ) and post-herpetic neuralgia (PHN) are painful con-
ditions that can have a substantial negative impact on patients’ lives. UK-specific
patient reported outcome (PRO) data on the debilitating impact of these conditions
is limited, however. A large-scale UK cross-sectional study, therefore, has recently
been conducted to address these limitations and further inform the scientific com-
munity. Findings from this study are summarised. METHODS: A combined total of
382 HZ and PHN patients over the age of 50 were recruited from 49 sites throughout
the UK. Participants were required to complete validated PRO measures of pain and
health-related quality of life (HRQoL), including the Zoster Brief Pain Inventory
(ZBPI) and the Medical Outcomes Study Short-Form 36 (SF-36). RESULTS: Pain was
a prominent symptom among patients, with more than 50% reporting experiencing
pain in the preceding 24 hours at levels typically considered to have a significant
impact on HRQoL (i.e. ZBPI worst pain 5). This was reflected in SF-36 domain and
summary scores that were significantly lower in HZ and PHN patients compared to
age-matched norms (p  0.05). When compared to normative samples, clinically
meaningful differences were observed among HZ and PHN samples across SF-36
domains assessing aspects of physical and mental well-being. In both groups,
HRQoL was inversely associated with levels of reported pain. CONCLUSIONS: Find-
ings indicate that the acute presentation of HZ and the development of PHN, the
most common complication of HZ and that can persist for several months, are
painful experiences that can have a significant impact on the physical and mental
wellbeing of HZ/PHN sufferers.
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OBJECTIVES: There is a growing debate regarding switching prescription (Rx) drugs
to over-the-counter (OTC) for chronic conditions as a viable option in the brand
lifecycle management and cost control. Further, patients are increasingly involved
in making informed treatment-related decisions. Using a novel patient registry, the
current study assessed satisfaction across ten widely used Rx and OTC medications
and evaluated the impact of Rx versus OTC status on treatment satisfaction for
these medications.METHODS:The registry recruited patients from multiple sourc-
es: physicians, pharmacies, and online referrals, to report ongoing medications on
www.MediGuard.org. A random sample of these patients was contacted to com-
plete the Treatment Satisfaction Questionnaire for Medication (TSQM) Version-I, a
14-item reliable and valid instrument to capture patients’ satisfaction with medi-
cation. The TSQM yields scores on four domains: effectiveness, side-effects, con-
venience, and global satisfaction. The study included patients on any of the ten Rx-
levothyroxine, metformin, atorvastatin, simvastatin, lisinopril, zolpidem, aripipra-
zole, esomeprazole, duloxetine, montelukast (n9,387) or OTC medications- ibu-
profen, acetaminophen, aspirin, multivitamin, cetrizine, omeprazole, omega,
naproxen, calcium carbonate, and loratadine (n7,226). Descriptive statistics and
regression analyses explored the differences in patients’ satisfaction across Rx
versus OTC medications. RESULTS: Overall, patients had mean (SD) age of 56.9
(12.4) years; 70.5% females and 73.8% White. The mean TSQM scores ranged from
61.4, 63.2 (acetaminophen, metformin) to 72.7, 76.4 (omeprazole, esomeprazole) on
effectiveness, from 93.0, 81.5 (cetirizine, aripiprazole) to 99.1, 97.6 (multivitamin,
esomeprazole) on side-effects, from 76.4, 78.1 (acetaminophen, metformin) to 88.2,
89.1 (loratadine, montelukast) on convenience and from 61.7, 61.1 (naproxen, met-
formin) to 73.8, 75.4 (cetirizine, esomeprazole) on global satisfaction. Compared to
Rx, OTC showed better side-effects profile and global satisfaction but had lower
effectiveness and convenience (p0.001) after adjusting for age, gender, race, self-
reported severity, and co-medications. CONCLUSIONS: The findings suggest that
differences in patients’ satisfaction profiles are associated with Rx versus OTC
medications.
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OBJECTIVES: We provided a comprehensive and detailed overview of the Spanish
burden of disease study for the year 2008. METHODS: We calculated disability-
adjusted life years (DALYs) at a country level using the methodology developed in
the Global Burden of Disease (GBD) study. DALYs were divided into years of life lost
because of premature mortality (YLLs) and years of life lived with disability (YLDs),
and are presented by sex and by age groups. Results were obtained using Spanish
specific-mortality data for the year 2008 and morbidity data estimated for Euro-A
region (European countries with very low mortality, including Spain) of the GBD
study. Data were analysed and prepared in GesMor and Epidat software. RESULTS:
In the year 2008, DALYs lost due to all diseases and injuries was estimated at 5.1
million (DALY rate per 1000 Spanish people of all ages and both sexes: 111.0). From
the total number of DALYs, 41.4% were due to premature mortality (YLLs) and
58.6% were due to disability (YLDs). Chronic non-communicable diseases ac-
counted for 89.2% of the total number of DALYs. The three main causes of DALYs
were neurological and mental disorders (29.9%), malignant neoplasms (15.8%), and
cardiovascular diseases (12.5%). The leading specific causes of DALYs were unipo-
lar depression (5.5%), ischaemic heart disease (5.5%), lung cancer (5.3%) and alcohol
abuse (4.7%) among males, and unipolar depression (11.7%), dementias (10.0%),
hearing loss (4.2%) and cerebrovascular disease (3.5%) among females.
CONCLUSIONS: Measuring DALYs specifically for Spain provides a systematic
analysis of health losses at a population level. The findings from this study suggest
that chronic non-communicable diseases would benefit from increased evidence-
based public health actions.
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OBJECTIVES:Calculate the country-level scores for the SF-36v2 subscales and com-
ponents for women with idiopathic menorrhagia treated with LNG-IUS; explore
between-country variability in HRQL experience of this condition; and evaluate the
treatment effect in different geographical settings. METHODS: Baseline and 12-
month data from a prospective, observational study of women with idiopathic
menorrhagia from 9 countries (Bulgaria, Croatia, India, Jordan, Romania, Russia,
Saudi Arabia, Serbia and Montenegro, and Turkey) were analyzed. Scores were
calculated for each of the eight domains and Physical and Mental component sum-
maries (PCS and MCS) of the SF-36v2. Hierarchical modeling was applied to account
for nested nature of observations within the countries. Frequentist mixed effects
regressions in STATA and Bayesian Markov Chain Monte Carlo simulation in Win-
BUGS were used to calculate country-level estimates, controlling for covariates.
RESULTS: Idiopathic menorrhagia negatively affects HRQL in different geographic
settings; in most countries baseline mean MCS scores are more than one standard
deviation (10 units) below the normative UK mean. Between-country variability
was confirmed in Bayesian and Frequentists analysis for baseline subscales (range:
36-86) and MCS and PCS (range: 35-51), indicating variation in experience with
menorrhagia. In general, 12-month estimates were much higher than those at
baseline, indicating substantial improvement in HRQL while on treatment, regard-
less of country. In addition, there was a consistent, positive relationship of haemo-
globin with the SF-36v2 subscales and the MCS. CONCLUSIONS:Women in 9 coun-
tries in the study are negatively affected by menorrhagia, though country-level
variation was seen. Improvement in HRQL while on treatment was consistent
across geographic settings. Exploration of potential country- or patient-level ef-
fects is recommended in future research.
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OBJECTIVES: Assess the impact of the treatment of urinary disorders of the lower
urinary tract related to benign prostatic hypertrophy (BPH) using medical treat-
ment under actual conditions of use. METHODS: A pragmatic cohort of patients
treated medically, was followed up for 6 months, using several validated question-
naires: IPSS, MSF4, and SF12. RESULTS:A total of 146 patients treated with Serenoa
Repens (hexanic extract) were evaluated, the mean age was 65.64 8.82 years, and
on average the diagnosis had been made 11 months previously. At 6 weeks, the IPSS
was significantly improved (p0.0001). This improvement in the IPSS score be-
tween 6 weeks (11.086.17) and inclusion (15.056.80) was 4 points. An improve-
ment was also observed at 3 months. At 6 months, the p-value was also significant
(p0.0001). The improvement in the IPSS score between 6 months (7.78423) and
inclusion (14.796.90) was 7 points.The physical dimension (50.187.39 at inclu-
sion) of the SF12 improved significantly (p0.0005) from the 6th week (52.466.10),
an improvement (2.51 points) that was confirmed at 6 months (52.076.54)
(p0.0052) in comparison with inclusion (49.567.53). The mental dimension
(49.187.63 at inclusion) of the SF12 improved significantly (p0.0069) at 6 month
(51.816.59). Improvement of 2.63 points. The MSF4 was unchanged.
CONCLUSIONS:We observed an improvement in the IPSS score from the 6th week;
this statistical improvement was confirmed by a significant clinical improvement
in the 6th month. This favourable progression is consistent with the improvement
observed for both dimensions of the SF12.
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OBJECTIVES: The aim of this study was to measure Health Related Quality of Life
among Pharmacy students at Medical University of Warsaw. METHODS: In March
2011, students from the Faculty of Pharmacy, Medical University of Warsaw were
surveyed with a set of HRQoL questionnaires. The survey was conducted in the
middle of the semester, when students have no exams, nor tests and was a part of
long-term Pharmacoeconomic Student Chapter’s project. Students self-completed
pen and pencil versions of questionnaires and didn’t receive any compensation.
They were asked to give information regarding sex, age, year of study, average
grade during the previous year of study and to complete final official Polish version
of EQ-5D-5L, followed by EQ-VAS, SF-36 v.1 and EQ-5D-3L. RESULTS: Three hun-
dred eighty three students were approached, 369 responded to EQ-5D-5L and SF-36
and were included in the final analysis. Missing data included: sex in 1 respondent,
age in 2 and EQ-VAS in 6 respondents. Concerning SF-36 dimensions, students
reported major problems in vitality 53.69  18.47 as opposed to physical function-
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